Macaya Douoguih
Janssen (Switzerland)(CH)Janssen (Netherlands)(NL)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Viral Infections and Outbreaks Research, Hepatitis B Virus Studies, COVID-19 Clinical Research Studies, Vaccine Coverage and Hesitancy
Most-Cited Works
- → Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19(2021)2,574 cited
- → Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine(2021)1,161 cited
- → Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans(2021)346 cited
- → Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines(2016)324 cited
- → Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19(2021)315 cited
- → Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination(2021)253 cited
- → Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S(2022)249 cited
- → Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania(2019)150 cited
- → Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial(2020)141 cited
- → Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults(2023)141 cited